Increasing the chances for platinum-sensitive ovarian cancer patients.

Future oncology (London, England) (2013-11-15)
Antonio González
RESUMO

Ovarian carcinoma is still one of the most common causes of death from cancer in the western world. Despite high sensitivity to chemotherapy, the majority of patients will relapse within 3 years. In this article the focus is centered on patients who have a late relapse (>12 months). Carboplatin-based regimens are the backbone of treatment for this group, producing clinical benefit with higher rates for progression-free and overall survival. However, not all patients can continue with platinum owing to loss of activity or toxicity (hypersensitivity, neurotoxicity and ototoxicity). In particular, hypersensitivity reactions to carboplatin are a concern and have been reported in approximately 15-20% of women receiving the drug. When expectations for a positive outcome with carboplatin are good, desensitization protocols may be useful so as to continue treatment. If platinum-based regimens are not possible then alternative forms of treatment are required; additional research efforts are being directed towards the development of nonplatinum-based therapies. Promising results have been obtained with the combination of trabectedin plus pegylated liposomal doxorubicin, providing encouragement that it will be a viable option for patients with recurrent ovarian cancer who cannot be treated with a platinum-based chemotherapeutic option.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
Platinum, wire, diam. 0.5 mm, 99.99% trace metals basis
Sigma-Aldrich
Platinum, foil, thickness 0.025 mm, 99.9% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 0.25 mm, 99.9% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 0.5 mm, 99.9% trace metals basis
Sigma-Aldrich
Platinum, gauze, 100 mesh, 99.9% trace metals basis
Sigma-Aldrich
Platinum black, black, powder, ≤20 μm, ≥99.95% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 1.0 mm, 99.9% trace metals basis
Sigma-Aldrich
Platinum, foil, thickness 0.05 mm, 99.99% trace metals basis
Sigma-Aldrich
Platinum, powder, 99.995% trace metals basis
Sigma-Aldrich
Platinum, gauze, 52 mesh, 99.9% trace metals basis
Sigma-Aldrich
Platinum, nanopowder, <50 nm particle size (TEM)
Sigma-Aldrich
Platinum, wire, diam. 2.0 mm, 99.9% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 0.10 mm, 99.99% trace metals basis
Sigma-Aldrich
Platinum, powder, ≤10 μm, 99.9% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 0.25 mm, 99.99% trace metals basis
Sigma-Aldrich
Platinum black, fuel cell grade, ≥99.9% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 0.076 mm, ≥99.99% trace metals basis
Sigma-Aldrich
Platinum, foil, thickness 0.125-0.135 mm, 99.9% trace metals basis
Sigma-Aldrich
Platinum, foil, thickness 1.0 mm, 99.99% trace metals basis
Sigma-Aldrich
Platinum, foil, thickness 0.25 mm, 99.99% trace metals basis
Sigma-Aldrich
Platinum, nanopowder, 200 nm particle size (SEM), 99.9% (metals basis)
Sigma-Aldrich
Platinum, wire, diam. 0.25 mm, thermocouple grade
Sigma-Aldrich
Platinum, wire, diam. 0.127 mm, 99.99% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 1.0 mm, 99.99% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 0.20 mm, ≥99.99% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 0.127 mm, 99.9% trace metals basis
Sigma-Aldrich
Platinum, powder (coarse), 99.99% trace metals basis
Sigma-Aldrich
Platinum black, low bulk density, ≥99.9% trace metals basis
Platinum, wire reel, 0.1m, diameter 1.0mm, annealed, may be used as one component of a thermocouple, 99.99%
Platinum, wire reel, 1m, diameter 0.3mm, annealed, may be used as one component of a thermocouple, 99.99%

Redes sociais

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Pesquisa. Desenvolvimento. Produção.

Somos um fornecedor global líder para o setor de ciências biológicas, com soluções e serviços para pesquisa, desenvolvimento e produção de biotecnologia, além de produção e desenvolvimento de terapias farmacológicas com medicamentos.

© 2021 Merck KGaA, Darmstadt, Alemanha e/ou suas filiais. Todos os direitos reservados.

A reprodução não autorizada de quaisquer materiais deste site é estritamente proibida.